Search Results - "Vasudevamurthy, Ashwin"

Acute Promyelocytic Leukemia After Treatment of Metastatic Castration-Resistant Prostate Cancer With Radium-223 by Odo, Ugochukwu, Vasudevamurthy, Ashwin K., Sartor, Oliver

Get full text

Estrogen-mediated activation of the H875Y androgen receptor mutation in a prostate cancer patient by Vasudevamurthy, A.K, Ledet, E, Garvey, C, Lewis, B, Sartor, O

Get full text

181 A Rare and Aggressive Gamma-Delta (γδ) T-Cell Lymphoma, NOS Presenting as Heart Failure Without Leukocytosis: Clinicopathologic Course and Autopsy Findings by Rifkin, Lucas, Atkinson, Jeremy, Vasudevamurthy, Ashwin, Schmieg, John

“…Abstract A 54-year-old man presenting with acute onset dyspnea on exertion in the absence of leukocytosis was found with global hypokinesis and 20%-25% EF on…”
Get full text

Treatment sequencing of abiraterone and enzalutamide in patients with mCRPC by Feibus, Allison H., Vasudevamurthy, Ashwin, Guccione, Jeffrey R., Ledet, Elisa M., Cotogno, Patrick, Manogue, Charlotte, Ernst, Emma M., Lewis, Brian E., Silberstein, Jonathan L., Sartor, Oliver

“…Abstract only 233 Background: Abiraterone (Abi) and Enzalutamide (Enza) are among the treatment modalities available for treating metastatic castrate-resistant…”
Get full text

Early assessment of PSA response in patients with mCRPC treated with enzalutamide and abiraterone by Feibus, Allison H., Guccione, Jeffrey R., Vasudevamurthy, Ashwin, Ledet, Elisa M., Cotogno, Patrick, Manogue, Charlotte, Ernst, Emma M., Lewis, Brian E., Silberstein, Jonathan L., Sartor, A. Oliver

“…Abstract only e574 Background: Abiraterone (Abi) and enzaleutamide (Enza) are first-line agents for the treatment of metastatic castrate-resistant prostate…”
Get full text

Targeting MALT1 with the Small Molecule Inhibitor MI2 Induces a Caspase-Dependent Apoptosis and Inhibits the NF-κb Pathway in Chronic Lymphocytic Leukemia Primary Cells by Tanios, Georges, Lobelle-Rich, Patricia, Vasudevamurthy, Ashwin, Atkinson, Thomas S., Baghian, Ali, Liu, Delong, Safah, Hana, Flemington, Erik K., Saba, Nakhle S.

“…Targeting the B-cell receptor (BCR) pathway in chronic lymphocytic leukemia (CLL) with the Bruton Tyrosine Kinase (BTK) inhibitor Ibrutinib has transformed the…”
Get full text